Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment-Reference-Cited by-同舟云学术

Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment

Published:2015-03-09 Issue:8 Volume:29 Page:1648-1655
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Eckert C,Hagedorn N,Sramkova L,Mann G,Panzer-Grümayer R,Peters C^ORCID,Bourquin J-P,Klingebiel T,Borkhardt A^ORCID,Cario G,Alten J,Escherich G,Astrahantseff K,Seeger K,Henze G,von Stackelberg A

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu201559.pdf

Reference37 articles.

1. Borgmann A, von Stackelberg A, Hartmann R, Ebell W, Klingebiel T, Peters C et al. Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis. Blood 2003; 101: 3835–3839.

2. Gaynon PS . Childhood acute lymphoblastic leukaemia and relapse. Br J Haematol 2005; 131: 579–587.

3. Nguyen K, Devidas M, Cheng SC, La M, Raetz EA, Carroll WL et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia 2008; 22: 2142–2150.

4. Parker C, Waters R, Leighton C, Hancock J, Sutton R, Moorman AV et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet 2010; 376: 2009–2017.

5. Bailey LC, Lange BJ, Rheingold SR, Bunin NJ . Bone-marrow relapse in paediatric acute lymphoblastic leukaemia. Lancet Oncol 2008; 9: 873–883.

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?;Blood Reviews;2024-08

2. Measurable residual disease (MRD)-testing in haematological and solid cancers;Leukemia;2024-04-18

3. Nelarabine-containing salvage therapy and conditioning regimen in transplants for pediatric T-cell acute lymphoblastic leukemia and lymphoma;International Journal of Hematology;2024-02-01

4. Minimal residual disease predicts outcomes in KMT2A‐rearranged but not KMT2A‐germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study AALL0631;Pediatric Blood & Cancer;2023-05-31

5. Phase 2 study of combination chemotherapy with bortezomib in children with relapsed and refractory acute lymphoblastic leukemia;International Journal of Hematology;2023-05-01